494 related articles for article (PubMed ID: 19140565)
1. Clinical utility of the assessment of fecal calprotectin in Leśniowski-Crohn's disease.
Eder P; Stawczyk-Eder K; Krela-Kaźmierczak I; Linke K
Pol Arch Med Wewn; 2008 Nov; 118(11):622-6. PubMed ID: 19140565
[TBL] [Abstract][Full Text] [Related]
2. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease.
D'Haens G; Ferrante M; Vermeire S; Baert F; Noman M; Moortgat L; Geens P; Iwens D; Aerden I; Van Assche G; Van Olmen G; Rutgeerts P
Inflamm Bowel Dis; 2012 Dec; 18(12):2218-24. PubMed ID: 22344983
[TBL] [Abstract][Full Text] [Related]
3. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI.
Schoepfer AM; Beglinger C; Straumann A; Trummler M; Vavricka SR; Bruegger LE; Seibold F
Am J Gastroenterol; 2010 Jan; 105(1):162-9. PubMed ID: 19755969
[TBL] [Abstract][Full Text] [Related]
4. Association between disease duration and usefulness of fecal calprotectin measurement in patients with Crohn's disease.
Eder P; Stawczyk-Eder K; Łykowska-Szuber L; Krela-Kaźmierczak I; Klimczak K; Szymczak A; Szachta P; Linke K
Pol Arch Med Wewn; 2014; 124(1-2):51-7. PubMed ID: 24424551
[TBL] [Abstract][Full Text] [Related]
5. Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings.
Sipponen T; Savilahti E; Kolho KL; Nuutinen H; Turunen U; Färkkilä M
Inflamm Bowel Dis; 2008 Jan; 14(1):40-6. PubMed ID: 18022866
[TBL] [Abstract][Full Text] [Related]
6. A prospective study of fecal calprotectin and lactoferrin as predictors of small bowel Crohn's disease in patients undergoing capsule endoscopy.
Bar-Gil Shitrit A; Koslowsky B; Livovsky DM; Shitrit D; Paz K; Adar T; Adler SN; Goldin E
Scand J Gastroenterol; 2017 Mar; 52(3):328-333. PubMed ID: 27841040
[TBL] [Abstract][Full Text] [Related]
7. Validation of a point-of-care desk top device to quantitate fecal calprotectin and distinguish inflammatory bowel disease from irritable bowel syndrome.
Sydora MJ; Sydora BC; Fedorak RN
J Crohns Colitis; 2012 Mar; 6(2):207-14. PubMed ID: 22325175
[TBL] [Abstract][Full Text] [Related]
8. Impact of disease location on fecal calprotectin levels in Crohn's disease.
Gecse KB; Brandse JF; van Wilpe S; Löwenberg M; Ponsioen C; van den Brink G; D'Haens G
Scand J Gastroenterol; 2015 Jul; 50(7):841-7. PubMed ID: 25636819
[TBL] [Abstract][Full Text] [Related]
9. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.
Langhorst J; Elsenbruch S; Koelzer J; Rueffer A; Michalsen A; Dobos GJ
Am J Gastroenterol; 2008 Jan; 103(1):162-9. PubMed ID: 17916108
[TBL] [Abstract][Full Text] [Related]
10. Serum calprotectin as a biomarker for Crohn's disease.
Meuwis MA; Vernier-Massouille G; Grimaud JC; Bouhnik Y; Laharie D; Piver E; Seidel L; Colombel JF; Louis E;
J Crohns Colitis; 2013 Dec; 7(12):e678-83. PubMed ID: 23845231
[TBL] [Abstract][Full Text] [Related]
11. Faecal calprotectin as a novel biomarker for differentiating between inflammatory bowel disease and irritable bowel syndrome.
Chang MH; Chou JW; Chen SM; Tsai MC; Sun YS; Lin CC; Lin CP
Mol Med Rep; 2014 Jul; 10(1):522-6. PubMed ID: 24788223
[TBL] [Abstract][Full Text] [Related]
12. Accuracy of fecal calprotectin for the prediction of endoscopic activity in patients with inflammatory bowel disease.
Jusué V; Chaparro M; Gisbert JP
Dig Liver Dis; 2018 Apr; 50(4):353-359. PubMed ID: 29396129
[TBL] [Abstract][Full Text] [Related]
13. Faecal calprotectin: a new marker for Crohn's disease?
Wassell J; Dolwani S; Metzner M; Losty H; Hawthorne A
Ann Clin Biochem; 2004 May; 41(Pt 3):230-2. PubMed ID: 15117438
[TBL] [Abstract][Full Text] [Related]
14. A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn's disease.
Lobatón T; López-García A; Rodríguez-Moranta F; Ruiz A; Rodríguez L; Guardiola J
J Crohns Colitis; 2013 Dec; 7(12):e641-51. PubMed ID: 23810085
[TBL] [Abstract][Full Text] [Related]
15. Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease.
Canani RB; Terrin G; Rapacciuolo L; Miele E; Siani MC; Puzone C; Cosenza L; Staiano A; Troncone R
Dig Liver Dis; 2008 Jul; 40(7):547-53. PubMed ID: 18358796
[TBL] [Abstract][Full Text] [Related]
16. Fecal calprotectin and S100A12 have low utility in prediction of small bowel Crohn's disease detected by wireless capsule endoscopy.
Sipponen T; Haapamäki J; Savilahti E; Alfthan H; Hämäläinen E; Rautiainen H; Koskenpato J; Nuutinen H; Färkkilä M
Scand J Gastroenterol; 2012 Jul; 47(7):778-84. PubMed ID: 22519419
[TBL] [Abstract][Full Text] [Related]
17. Fecal calprotectin and C-reactive protein are associated with positive findings in capsule endoscopy in suspected small bowel Crohn's disease.
Egea Valenzuela J; Pereñíguez López A; Pérez Fernández V; Alberca de Las Parras F; Carballo Álvarez F
Rev Esp Enferm Dig; 2016 Jul; 108(7):394-400. PubMed ID: 27312194
[TBL] [Abstract][Full Text] [Related]
18. FECAL CALPROTECTIN: levels for the ethiological diagnosis in Brazilian patients with gastrointestinal symptoms.
Kotze LM; Nisihara RM; Marion SB; Cavassani MF; Kotze PG
Arq Gastroenterol; 2015; 52(1):50-4. PubMed ID: 26017083
[TBL] [Abstract][Full Text] [Related]
19. [Fecal calprotectin in differential diagnosis of irritable bowel syndrome].
Li XG; Lu YM; Gu F; Yang XL
Beijing Da Xue Xue Bao Yi Xue Ban; 2006 Jun; 38(3):310-3. PubMed ID: 16778979
[TBL] [Abstract][Full Text] [Related]
20. Comparison of three commercial fecal calprotectin ELISA test kits used in patients with Inflammatory Bowel Disease.
Mirsepasi-Lauridsen HC; Bachmann Holmetoft U; Ingdam Halkjær S; Angeliki Krogfelt K; Munk Petersen A
Scand J Gastroenterol; 2016; 51(2):211-7. PubMed ID: 26359672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
